Andrew Haddad, PharmDGraduate Student
Program: PHD Track: Clinical Pharmaceutical Sciences Advisor: Philip E. Empey, PharmD, PhD, FCCP
Andrew completed his B.S. in Biochemistry and molecular biology from the University of California, Davis and his PharmD from the University of Pittsburgh in 2021. Andrew began his PhD studies in Clinical Pharmaceutical Sciences at Pitt in 2021 under the mentorship of Dr. Philip Empey. His research interests include pharmacogenomics, big data, pharmacokinetics, and critical care.
Ilchenko S, Haddad A, Sadana P, Recchia F, Sadygov R, Kasumov T. Calculation of the Protein Turnover Rate Using the Number of Incorporated 2H Atoms and Proteomics Analysis of a Single Labeled Sample. Anal Chem. 2019 Nov 19;91(22):14340-14351.
Wagner A, Campos N, Robbins M, Haddad A, Cunningham H, Christiansen B, Haudenschild D. Acute Changes in NADPH Oxidase 4 in Early Post-Traumatic Osteoarthritis. J Orthop Res. 2019 Nov;37(11):2429-2436.
Lee K, Haddad A, Osme A, Kim C, Borzou A, Ilchenko S, Allende D, Dasarathy S, McCullough A, Sadygov R, Kasumov T. Hepatic Mitochondrial Defects in a Mouse Model of NAFLD Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. Mol Cell Proteomics. 2018 Dec;17(12):2371-2386.
2022 - CPIC-PGRN Presidential Poster Award
2019 - John P. Curran Scholarship
2022 - All of Us Research Program Researchers Convention. “Pharmacogenomic medication exposures within All of Us Research Program Participants.”